Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413354 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13293994 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL31413355 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL9885494 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL584232 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| Hydrochloric Acid SCHEMBL30944523 | 0.98 | ADH1A (0.44) | ADH1AKITFLT1KDRABL2 | |
| Hydrochloric Acid SCHEMBL16933151 | 0.98 | ADH1A (0.44) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13564476 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13564469 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL14527500 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109789158-B | RUNX inhibitors | 国立大学法人京都大学 | 2022-06-03 | — | — | CN | claimed |
| CN-122081247-A | Oncolytic vaccinia virus and recombinant viruses and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4727562-A1 | USE OF CD200AR-L FOR ENHANCING ADOPTIVE T-CELL THERAPY | Elias Animal Health (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12553047-B2 | Engineered immunostimulatory bacterial strains and uses thereof | Actym Therapeutics, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4658315-A1 | POLYMER-DRUG CONJUGATES | Primelink Biotherapeutics (Shenzhen) Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250345369-A1 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | ACTYM THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4613276-A2 | IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS | Actym Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4593832-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | Keyzell Holding S.L. (ES) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | disclosed |
| CN-115068626-A | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220280577-A1 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | Actym Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-109789158-B | RUNX inhibitors | 国立大学法人京都大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20220154136-A1 | IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS | Actym Therapeutics, Inc. | 2022-05-19 | — | — | US | disclosed |
| US-20220135980-A1 | IMMUNOSTIMULATORY BACTERIA ENGINEERED TO COLONIZE TUMORS, TUMOR-RESIDENT IMMUNE CELLS, AND THE TUMOR MICROENVIRONMENT | Actym Therapeutics, Inc. | 2022-05-05 | — | — | US | disclosed |
| US-20220119824-A1 | IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS | Actym Therapeutics, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20220112501-A1 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | Actym Therapeutics, Inc. | 2022-04-14 | — | — | US | disclosed |
| CN-105813655-B | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022036159-A2 | IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS | Actym Therapeutics, Inc. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11242528-B2 | Engineered immunostimulatory bacterial strains and uses thereof | Actym Therapeutics, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | IRF3, IFNAR1, CXCL10 | ADH1A 4729/4885KIT 2028/4885FLT1 523/4885 |
| US-20220119824-A1 | IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS | TLR5, TLR1, MYD88 | ADH1A 4818/4885KIT 4601/4885FLT1 3671/4885 |
| US-12553047-B2 | Engineered immunostimulatory bacterial strains and uses thereof | CD274, ENTPD1, PDCD1LG2 | ADH1A 2807/4885KIT 1090/4885FLT1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.